AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma ...

NDA requesting modification of liver monitoring for FILSPARI in IgAN accepted for review by FDA; PDUFA target action date of August 28, 2025 SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Travere ...

Shanghai Huilun Pharmaceutical Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase binding moiety coupled to an interleukin-1 ...

Consider the benefits and risks before using ALYFTREK in these patients. If ALYFTREK is used in these patients, closely monitor for adverse reactions as clinically appropriate Reduced Effectiveness ...

If ALYFTREK is used in these patients, closely monitor for adverse reactions as clinically appropriate Reduced Effectiveness with Concomitant Use With CYP3A Inducers Following concomitant use of ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...

Beyond the liver risks, the warnings and precautions section of the prescribing information includes notes about hypersensitivity reactions, reduced effectiveness in patients on CYP3A inducers ...